DeepMeds

Safer Contrast-Enhanced MRI with 80% Less Gadolinium

DeepMeds' DeepGAD™ synthesizes full-dose equivalent images from only 20% dose—reducing patient risk, cost, and environmental burden.

Prospective clinical study

Provisional Utility Patent Pending

PACS & OEM integration-ready

Clinically Validated Performance

80% GBCA Dose Reduction

Full-dose-equivalent images from just 20% contrast agent volume

Non-Inferior Diagnostic Performance

Blinded neuroradiologist reader study (n=101)

Higher SNR & Vessel Conspicuity

Improved signal characteristics vs full-dose images

Quantitative Validation

SSIM ≈ 86% ±12.1, PSNR ≈ 27 ±3 dB

20% Dose

20% dose MRI scan

DeepGAD™ Enhanced

AI enhanced MRI scan